Latest News About Rsv Vaccine Australia

Short answer: Australia has approved and rolled out RSV vaccines for older adults, with ongoing coverage and funding discussions; latest major developments center on TGA approval in 2024 and subsequent availability and funding debates in 2025–2026.

Details you might find helpful:

• Regulatory firsts: Australia approved AREXVY, an RSV vaccine for adults 60+, marking the country’s first RSV vaccine approval in this age group. This approval came from the Therapeutic Goods Administration in January 2024. This is the core regulatory milestone driving subsequent rollout.[2]
• Availability and access: After approval, AREXVY began to be available in Australia, with some discussions about funding through the National Immunisation Program and private prescriptions. The vaccine is typically given as a single dose and targets lower airway RSV disease in older adults.[2]
• Public health context: RSV is a seasonal respiratory virus; in Australia, vaccination discussions have included whether to subsidize the vaccine and make it free under public programs, with media coverage in 2024–2025 highlighting calls for broader funding as RSV cases and winter demand rose.[10][2]
• Ongoing public coverage: Media outlets in Australia have reported on calls for free or subsidized RSV vaccination for older adults, as well as updates on vaccine availability during winter seasons, indicating a dynamic funding and access landscape post-approval.[4][5][9]
• Related messaging: Australian health authorities provided RSV immunisation resources and schedules for providers, underscoring ongoing guidance as vaccines expand beyond initial rollout.[6]

If you’d like, I can pull the most recent status from Australian health department updates or major outlets and summarize any changes to funding or eligibility rules. I can also compile a brief timeline of key milestones (approval, first shipments, funding debates) with inline citations.